Investigating the effectiveness of cannabidiol (CBD) for bipolar depression

PURPOSE OF THIS STUDY

The purpose of this study is to examine whether cannabidiol, also known as CBD, is effective in treating symptoms of depression in people diagnosed with bipolar disorder type I or II when added to their regular medications.

WHO CAN PARTICIPATE

You may be eligible to participate if you:

- are between 19 to 70 years old
- have been diagnosed with bipolar disorder
- are currently experiencing a depressive episode
- are taking a medication for mood stabilization (e.g. lithium, risperidone, valproate/epival, olanzapine, quetiapine, aripiprazole, and/or lamotrigine)

WHAT IS INVOLVED

Participants will be randomly assigned CBD or an identical placebo to take daily for six weeks. The study is double-blind, meaning that neither the participant nor the study staff will know which treatment they are receiving. Participants will have five clinical visits and one follow-up phone call over eight to 10 weeks. The total time commitment for the study is estimated to be seven to eight hours.

CONTACT INFORMATION

Shannon Reid, Research Coordinator
Phone: 604-822-8045
Email: bipolar.research@ubc.ca

STUDY TIME/ DURATION

October 2023 to December 2030

STUDY LOCATION

Mood Disorders Centre, Djavad Mowafaghian Centre for Brain Health
2215 Wesbrook Mall, Vancouver

PRINCIPAL INVESTIGATOR

Dr. Lakshmi Yatham
Professor, Department of Psychiatry, UBC
Research Investigator, VCH Research Institute

To learn more about this study, visit vchri.ca/participate

Version date: November 2, 2023